2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2927

What Are the Optimal MRI Lesion Cut-Offs That Define Active and Structural Lesions in the Sacroiliac Joint As Being Typical of Axial Spondyloarthritis By Expert Readers?
Abstract Number: 2928

Validation of New Systemic Lupus Erythematosus Classification Criteria
Abstract Number: 2929

Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Abstract Number: 2930

Prospective Comparison of Remission and Lupus Low Disease Activity State – Effect on Disease Outcomes in Systemic Lupus Erythematosus
Abstract Number: 2931

Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects
Abstract Number: 2932

Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology
Abstract Number: 2933

Non-Invasive Tape Sampling Reveals RNA Gene Clusters in Cutaneous Lupus Erythematosus That Discriminate Affected from Unaffected and Healthy Volunteer Skin
Abstract Number: 2934

Myocardial Microscopic Fibrosis Assessed By T1 Mapping Sequences on Cardiac Magnetic Resonance Imaging Predicts Cardiac Events in Systemic Sclerosis: Data from a Prospective Cohort Study on 40 Patients
Abstract Number: 2935

A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification
Abstract Number: 2936

Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis
Abstract Number: 2937

Anti-Vinculin Antibodies in Systemic Sclerosis (SSc): A Potential Biomarker Linking Vascular and Gastrointestinal System Involvement in Two Phenotypically Distinctive SSc Groups
Abstract Number: 2938

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (ACR CRISS) in a Phase 3 Randomized Controlled Trial
Abstract Number: 2939

Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis
Abstract Number: 2940

Complementary Practices As Alternatives to Pain: Effectiveness of a Pain Management Program for Patients in an Orthopedic Clinic
Abstract Number: 2941

Reach and Effectiveness of a Health Communications Campaign Promoting Self Management Education: Results of a Pilot Test of the Learn More. Feel Better. Campaign

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].